Life Edit Therapeutics
John Russell currently serves as the Director of Laboratory Automation at Life Edit Therapeutics, a position held since January 2022. Prior to this role, John worked as a Principal Scientist in Automation Sciences and Integration at KBI Biopharma from October 2018 to January 2022 and as a Lead Automation Consultant at LHR Automation between May 2015 and September 2018. With a focus on enabling automation in early drug discovery processes, John provides expertise in software and hardware support, particularly in plate handling, liquid handling, and compound management inventory systems. John’s earlier experience includes an Investigator role at GlaxoSmithKline from August 2004 to 2015, where responsibilities involved the purchase, maintenance, and method creation for laboratory automation suites, as well as designing processes for biological assays. John holds a Bachelor of Science degree in Science Education from North Carolina State University, earned in 2004.
Life Edit Therapeutics
Life Edit, an ElevateBio company, is a next-generation genome editing company that has built a highly innovative platform with one of the world’s largest and most diverse collections of novel RNA-guided nucleases (RGNs) and base editors. The platform allows Life Edit to target any genomic sequence and develop novel human therapeutics for the most challenging genetic diseases by enabling ex vivo engineering for cell therapies and regenerative medicines and in vivo delivery of gene therapies. In addition to developing its own pipeline of cell and gene therapies, Life Edit Therapeutics will continue to strengthen its platform of genome-editing enzymes, provide gene-editing expertise to strategic partners, and form other third-party partnerships to discover and develop new therapies.